Marine Natural Products: From Sea to Pharmacy | Ocean Science Lecture

Added:

The Scalability and Synthesis Bottleneck of Marine Natural Products

While marine natural products (MNPs) offer immense chemical diversity, critics highlight significant hurdles in translating these discoveries into viable pharmaceuticals. The primary obstacle is the 'supply problem': marine organisms often produce target compounds in miniscule quantities, and harvesting them at scale can cause severe ecological damage. Furthermore, MNPs typically possess highly complex, multi-ring chemical structures that are extraordinarily difficult and expensive to synthesize in a laboratory. Consequently, many pharmaceutical companies have shifted resources away from natural product screening toward synthetic chemistry, computer-aided drug design (CADD), and AI-driven de novo molecular generation. These modern approaches allow for the precise, rapid engineering of drug candidates with optimized pharmacological properties and reliable, scalable manufacturing pathways, avoiding the ecological, legal (such as biopiracy and Nagoya Protocol compliance), and technical bottlenecks associated with harvesting and replicating complex marine molecules.

Introduction to Organic Chemistry: Understanding chemical structures, functional groups, and secondary metabolites (natural products) produced by organisms.
Basic Microbiology and Marine Biology: Familiarity with marine ecosystems, biodiversity, and the physiological adaptations of marine microbes and invertebrates.
Fundamentals of Genetics and Molecular Biology: Core concepts of DNA sequencing, gene expression, and how genetic code dictates the synthesis of proteins and molecules.
The Drug Discovery Pipeline: General knowledge of how therapeutic agents are identified, tested, and approved for clinical use.
Advanced Bioinformatics and Genome Mining: Learning to use computational tools (such as antiSMASH) to identify biosynthetic gene clusters (BGCs) in microbial genomes.
Marine Pharmacology and Mechanisms of Action: Investigating how specific FDA-approved marine drugs (e.g., cytarabine, eribulin, brentuximab vedotin) target diseases at the cellular level.
Synthetic Biology and Metabolic Engineering: Exploring methods to heterologously express silent biosynthetic pathways in host organisms to scale up production of scarce marine compounds.
The Supply Problem and Sustainable Bioprospecting: Studying the ecological, chemical, and ethical challenges of sourcing marine natural products, including the impact of the Nagoya Protocol on international biodiversity sharing.
24.4K views558likes51:10@uctvOriginal Release: 2019-09-03

Marine microbes, particularly ocean-dwelling actinomycetes like Salinispora species, produce unique secondary metabolites that serve ecological functions such as defense and chemical communication, and these compounds represent a promising but underexplored source of new pharmaceuticals, with Salinisporamide A from Salinispora tropica currently in phase 3 clinical trials for cancer treatment as the first marine microbial natural product to reach this stage.